Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Lin AH et al. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. 1982 J. Clin. Invest. pmid:6290535
Mencia-Huerta JM et al. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages. 1982 J. Immunol. pmid:7086143
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Page CP et al. Platelet activation in asthma. 1982 N. Engl. J. Med. pmid:7088080
Chilton FH et al. Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 1982 J. Biol. Chem. pmid:6802816
Vargaftig BB et al. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. 1982 Thromb. Haemost. pmid:7135345
Sancho J et al. The effect of the injection of a synthetic platelet-activating factor (PAF-acether) on the fate of IgG aggregates in mice. 1982 Immunology pmid:7141463
Sybertz EJ et al. Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats. 1982 J. Pharmacol. Exp. Ther. pmid:7143227
Cabot MC et al. Metabolism of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by cell cultures. 1982 Life Sci. pmid:7162357
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Roubin R et al. Release of platelet-activating factor (PAF-acether) and leukotrienes C and D from inflammatory macrophages. 1982 Eur. J. Immunol. pmid:6122581
O'Flaherty JT Lipid mediators of inflammation and allergy. 1982 Lab. Invest. pmid:6126615
Pinckard RN The "new" chemical mediators of inflammation. 1982 Monogr Pathol pmid:6126808
Robeva R et al. [Changes in blood coagulation in glomerulonephritis]. 1982 Vutr Boles pmid:6219496
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Shukla SD and Hanahan DJ AGEPC (platelet activating factor) induced stimulation of rabbit platelets: effects on phosphatidylinositol, di- and triphosphoinositides and phosphatidic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6288030
Alonso F et al. Modulatory role of cyclic AMP in the release of platelet-activating factor from human polymorphonuclear leucocytes. 1982 Immunology pmid:6277775
Rao GH et al. Human platelet activation by an alkylacetyl analogue of phosphatidylcholine. 1982 Biochim. Biophys. Acta pmid:6280777
Ingraham LM et al. Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. 1982 Blood pmid:6282362
Valone FH et al. Specific binding of phospholipid platelet-activating factor by human platelets. 1982 J. Immunol. pmid:6286773
Lüscher EF The role of blood cells and of the vessel wall in the induction of intravascular coagulation. 1982 Klin. Wochenschr. pmid:6750223
Yasaka T et al. Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). 1982 J. Immunol. pmid:6278021
Morgan WK et al. Byssinosis: some unanswered questions. 1982 Am. Rev. Respir. Dis. pmid:6808880
Myśliwiec M and Myśliwiec B [Blood platelets, prostaglandin and complement interactions in inflammation]. 1982 Prz. Lek. pmid:6753039
Miller OV et al. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence. 1982 Biochim. Biophys. Acta pmid:6285985
Miller CL Infection in massively injured patients. 1982 Prog. Clin. Biol. Res. pmid:6757964
Bruni A and Palatini P Biological and pharmacological properties of phospholipids. 1982 Prog Med Chem pmid:6758038
Masugi F et al. [Platelet-activating factor and antihypertensive polar renomedullary lipid: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine]. 1982 Tanpakushitsu Kakusan Koso pmid:6758041
Modiano A and Belisario A [Recent information on PAF (Platelet Activating Factor) in hemocoagulative and immuno-allergic processes]. 1982 G Clin Med pmid:6762313
Marcus AJ et al. Arachidonic acid metabolism in endothelial cells and platelets. 1982 Ann. N. Y. Acad. Sci. pmid:6762834
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Camussi G et al. Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation. 1982 Blood pmid:6947829
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Smith RJ and Bowman BJ Stimulation of human neutrophil degranulation with 1-O-octadecyl-2-O-acetyl-SN-glyceryl-3-phosphorylcholine: modulation by inhibitors of arachidonic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6803804
De Clerck F and David JL Pharmacological control of platelet and red blood cell function in the microcirculation. 1981 Nov-Dec J. Cardiovasc. Pharmacol. pmid:6173539
Camussi G et al. Immune-induced leucopenia. A role for the aggregation of polymorphonuclear neutrophils in systemic lupus erythematosus (SLE). 1981 Jul-Sep Minerva Nefrol pmid:7329598
Camussi G et al. In vitro spasmogenic effect of platelet-activating factor on rabbit lung tissue. 1981 Jul-Sep Panminerva Med pmid:7335369
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
Shaw JO et al. Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). 1981 Biochim. Biophys. Acta pmid:7213765
Camussi G et al. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. 1981 Immunology pmid:6161885
O'Flaherty JT et al. Evidence for 5, 12-dihydroxy-6,8,10,14-eicosatetraenoate as a mediator of human neutrophil aggregation. 1981 Biochem. Biophys. Res. Commun. pmid:6277309
Marcus AJ et al. Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. 1981 Blood pmid:6457658
Deguchi K et al. [Blood platelet aggregation]. 1981 Nippon Rinsho pmid:6461781
Mencia-Huerta JM et al. Release of a slow-reacting substance from rabbit platelets. 1981 J. Clin. Invest. pmid:6119324
Heymans F et al. New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures. 1981 Biochim. Biophys. Acta pmid:7306563